Pharmacogenomics of methotrexate: Moving towards individualized therapy

Pharmacogenomics

Volumn 10, Issue 12, 2009, Pages 1887-1889

  Nersting, Jacob ^a   Schmiegelow, Kjeld ^b  

^a Mental Health Center Glostrup   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FOLIC ACID; METHOTREXATE; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; EDITORIAL; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; MUTATIONAL ANALYSIS; PHARMACOGENOMICS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR;

HUMANS; METHOTREXATE; PHARMACOGENETICS;

EID: 73649084093     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.148     Document Type: Editorial

References (24)

1. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA: Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin). N. Engl. J. Med. 238, 787-793 (1948).
2. Schmiegelow K: Advances in individual prediction of methotrexate toxicity: a review. Br. J. Haematol. 146, 489-503 (2009).
3. Braun J, Rau R: An update on methotrexate. Curr. Opin. Rheumatol. 21, 216-223 (2009).
4. Davidsen ML, Dalhoff K, Schmiegelow K: Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 30, 831-849 (2008).
5. Dervieux T, Greenstein N, Kremer J: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54, 3095-3103 (2006).
6. Krajinovic M, Moghrabi A: Pharmacogenetics of methotrexate. Pharmacogenomics 5, 819-834 (2004).
7. Toffoli G, Russo A, Innocenti F et al.: Effect of methylenetetrahydrofolate reductase 677C - >T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer 103, 294-299 (2003).
8. Patino-Garcia A, Zalacain M, Marrodan L, San-Julian M, Sierrasesumaga L: Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J. Pediatr. 154(5), 688-693 (2009).
9. Ranganathan P: An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 9, 439-451 (2008).
10. Campalani E, Arenas M, Marinaki AM, Lewis CM, Barker JN, Smith CH: Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J. Invest. Dermatol. 127, 1860-1867 (2007).
11. Herrlinger KR, Cummings JR, Barnardo MC, Schwab M, Ahmad T, Jewell DP: The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet. Genomics 15, 705-711 (2005).
12. Ulrich CM, Yasui Y, Storb R et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98, 231-234 (2001).
13. Robien K, Bigler J, Yasui Y et al.: Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol. Blood Marrow Transplant. 12, 973-980 (2006).
14. Whittle SL, Hughes RA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 43, 267-271 (2004).
15. Hayashi H, Fujimaki C, Daimon T, Tsuboi S, Matsuyama T, Itoh K: Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J. Clin. Pharm. Ther. 34, 355-361 (2009).
16. Belkov VM, Krynetski EY, Schuetz JD et al.: Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 93, 1643-1650 (1999).
17. Wessels JA, Huizinga TW, Guchelaar HJ: Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47, 249-255 (2008).
18. Bokkerink JP, Damen FJ, Hulscher MW, Bakker MA, De Abreu RA: Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia. Hamatol. Bluttransfus. 33, 110-117 (1990).
19. de Jonge R, Tissing WJ, Hooijberg JH et al.: Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 113, 2284-2289 (2009).
20. Deeken J: The Affymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther. 11, 260-268 (2009).
21. Schmiegelow K, Forestier E, Kristinsson J et al.: Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 3, 557-564 (2009).
22. Schmiegelow K, Schroder H, Gustafsson G et al.: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J. Clin. Oncol. 13, 345-351 (1995).
23. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Semin. Hematol. 46, 100-106 (2009).
24. Schmiegelow K, Pulczynska MK: Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? Am. J. Pediatr. Hematol. Oncol. 12, 462-467 (1990).